Trial reportInternational journal of cancer2020
A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer.
Trial report in International journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 34 citations in OpenAlex.
- Anlotinib plus oral fluoropyrimidine S-1 in refractory or relapsed small-cell lung cancer (SALTER TRIAL): a multicenter, single-arm, phase II trial.BMC cancer · 2024Trial
- Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial.Investigational new drugs · 2023Trial
- Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202).Frontiers of medicine · 2022Trial
- A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer.Thoracic cancer · 2022Trial
- Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer.Journal for immunotherapy of cancer · 2022Trial
- A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer.International journal of cancer · 2020Trial
- Application and mechanistic research of novel therapeutic strategies in cisplatin-resistant small cell lung cancer.Annals of medicine · 2026Review
- Efficacy and safety of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small-cell lung cancer: a systematic review and meta-analysis.Journal of thoracic disease · 2026Article
- New-Onset Arrhythmias in Advanced Lung Cancer Patients Undergoing Anlotinib Treatment.Cardiovascular toxicology · 2025Article
- Real-world efficacy and safety of anlotinib combined with chemotherapy for advanced pancreatic cancer: a retrospective study.Future science OA · 2025Article
- Efficacy and safety of tislelizumab plus anlotinib and irinotecan as second-line treatment for extensive-stage small cell lung cancer: a single-arm, open-label, phase II trial.EClinicalMedicine · 2025Article
- Are metformin-based combination approaches beneficial for non-small cell lung cancer: evidence from experimental and clinical studies.Military Medical Research · 2025Review
- Efficacy outcomes between tarlatamab and real-world physicians' choice of therapies for previously treated extensive stage small cell lung cancer.The oncologist · 2025Article
- A retrospective study of anlotinib in patients with persistent, recurrent or metastatic cervical and endometrial cancer.Translational cancer research · 2024Article
- Combination of Sintilimab and Anlotinib for Metastatic Osteosarcoma: A Case Report.OncoTargets and therapy · 2024Article
- Toripalimab combined with anlotinib for recurrent extensive‑stage small‑cell lung cancer: A case report.Experimental and therapeutic medicine · 2023Article
- A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer.Frontiers in endocrinology · 2023Article
- Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort.Annals of translational medicine · 2022Article
- Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report.Frontiers in endocrinology · 2022Article
- Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study.Clinical Medicine Insights. Oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this prospective phase II clinical trial was to investigate the efficacy and safety of anlotinib in patients with relapsed small cell lung cancer (SCLC). Forty-five patients with relapsed SCLC were enrolled and treated with anlotinib (one cycle of 12 mg daily for 14 days, discontinued for 7 days, and repeated every 21 days) until disease progression or intolerance of treatment. The primary end point was progression-free survival (PFS). Secondary end points were overall survival (OS), disease control rate (DCR), objective control rate (ORR) and toxicity. The median PFS was 4.1 months (95% confidence interval [CI] 2.4-5.8) and the median OS was 6.1 months (95% CI 2.2-10.0). The OS for the limited-stage subgroup was significantly longer than that of the extensive-stage subgroup (P = .02). The DCR was 67%, and the ORR was 11%. The most common adverse event was hypertension (13%), which was controlled well with antihypertensive drugs. In conclusion, anlotinib has likely efficacy in patients with relapsed SCLC, and the side effects can be well tolerated. A longer OS was observed in limited-stage SCLC patients treated with anlotinib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.